An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

January 31, 2025. More for You ...

© 2025 NBCUniversal Media, LLCApple®, Apple logo® and App Store® are registered trademarks of Apple Inc.

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), a biopharmaceutical ...

Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption ...

Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet) ...

The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.

The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).